FridayApr 13, 2018 11:09 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Expands Patented Drug Delivery Portfolio with New Breakthroughs

Novel drug delivery system scientifically proven to increase absorption, bioavailability and efficacy New U.S. patents awarded, strengthening company’s IP portfolio Wide variety of patent families with ranging applications Building off DehydraTECH™, its patented lipophilic drug delivery platform, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has received another new Notice of Allowance from the United States Patent and Trademark Office that protects the company’s processes for making specific compositions of matter for enhanced cannabinoid delivery (http://cnw.fm/yN7AQ). This latest announcement comes on the heels of Lexaria’s March 22, 2018, press release that announced its receipt of a Notice of Allowance for the…

Continue Reading

WednesdayApr 11, 2018 1:47 pm

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Provides Update on Bio-Cannabis Product Pipeline

Several proprietary products developed and ready to market in Canada, California and global markets Cannabis product sales expected to generate significant revenue Pivot’s IP portfolio includes global patents to cement its leading position in the cannabis industry On April 4, 2018, Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) published an update on the advancements of its industry-leading cannabis product pipeline (http://cnw.fm/37EFo). A newly developed 1% cannabidiol (CBD) oral micelle solution, created in collaboration with the company’s German technology partner, Solmic GmbH, is ready to market. The development of two topical creams using Pivot’s patented formulation and delivery systems…

Continue Reading

WednesdayApr 11, 2018 11:11 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Tech Promises Versatile Commercial Applications

DehydraTECH™ has been shown to improve the taste, smell, bioabsorption and bioavailability of high performance ingestible consumer products Lexaria is working to eliminate negative side effects and enhance the healthy benefits of a variety of bioactive compounds Research being conducted for healthier oral ingestion of vitamins, nicotine and opioids DehydraTECH™ is a unique enabling technology from Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) that increases the absorption rate of edible ingestion, delivering five to 10 times more of active ingredients than traditional edibles. This technology is not a competing technology but rather a complementary layer that provides a versatile range…

Continue Reading

TuesdayApr 10, 2018 10:43 am

Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) Growing Patent Portfolio Enables Commercialization, Defense of DehydraTECH

LXRP recently received a new U.S. patent allowance for ‘composition of matter’ related to its DehydraTECH™ platform’s delivery of cannabinoids; based on past experience, company expects formal granting of patent within 100 days Company filed new U.S. patent application for use of DehydraTECH to improve the speed of absorption of active pharmaceutical ingredients through the skin; compared to other commercial formulations, LXRP product exhibited up to a 225 percent increase in permeability LXRP gets primary revenue through third party licensing fees related to its proprietary and patented intellectual property; goal is to partner with leading firms globally to deliver best-in-class…

Continue Reading

FridayApr 06, 2018 2:00 pm

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Extracts Maximum Benefit from Cannabis Portfolio

Forecasts predict $55.8 billion valuation for medical cannabis market by 2025 Pivot Pharmaceuticals building portfolio of diverse tech for improving bioavailability of cannabinoid therapies Company’s leadership team builds on decades of experience in pharmaceutical arena For nutrition-conscious consumers, scanning food product labels is a requisite part of any trip to the grocery store, but a recent study by the U.S. Department of Agriculture’s Agricultural Research Service (http://cnw.fm/i21Ex) found that the old maxim ‘what you see isn’t always what you get’ holds true when it comes to certain foods like nuts. Even though pistachios, for example, may have 161.9 calories per ounce,…

Continue Reading

WednesdayApr 04, 2018 1:38 pm

Xanthic Biopharma Inc. Establishing a New Paradigm in Cannabinoid Delivery

Filed patents to protect company’s process and products Powderized cannabis products deliver precise CBD/THC dosing with superior cannabinoid solubility Signed strategic partnership and licensing agreement with Avitas CBD Water After thousands of years of human use, cannabis is now at the center of a new revolution. The medical efficacy of certain cannabinoids is now settled science, and numerous advanced therapeutic applications are currently in development. Recreational cannabis use has gained broad acceptance in multiple U.S. states and, in a few months, becomes legal across all of Canada. However, whether for medicinal or recreational purposes, there have been long-standing problems with…

Continue Reading

TuesdayApr 03, 2018 9:00 am

Infusion of Biotechnology Into Cannabis Market Leads to Booming Growth

CanadianCannabisWire Editorial Coverage: The tremendous growth of the licensed cannabis market has naturally led to an increase in research in this area. A number of specialist biotech companies have emerged, creating innovative cannabinoid applications. Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) (LXRP Profile) has developed technology to improve the palatability and speed of absorption of cannabinoid therapeutics, leading to a range of licensed products and related patents. Plant biotechnology company 22nd Century Group, Inc. (NYSE American: XXII) is altering the level of active ingredients in both cannabis and tobacco, allowing new strains to be grown for medical and other purposes.…

Continue Reading

CanadianCannabisWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 905.674.5977